Pfizer. BioNTech seek to revoke CureVac's patent infringement claims
02/09/2022 14:32
Sept 2 (Reuters) - Pfizer PFE.N and its German partner BioNTech BNTX.O have filed proceedings at the High Court of England & Wales seeking judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac's CVAC.O European patents, according to a regulatory filing on Friday. (Reporting by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028